← Eichor
Study identifier: NCT06311123 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Understanding Ozanimod's MOA Via Mass Cytometry in Ulcerative Colitis

Condition: Ulcerative Colitis · Ulcerative Colitis Chronic Moderate  ·  Sponsor: University of California, San Diego

PhaseN/A
Planned participants10
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this observational study is to learn about the mechanism of action of ozanimod in patients with ulcerative colitis (UC). The main questions it aims to answer are: 1. Prospectively assess the effects of ozanimod on the cellular composition of intestinal lamina propria and blood by deep immunophenotyping (CyTOF) of immune cell subsets prior and after the drug's administration. 2. Determine whether changes in cell subsets observed via mass cytometry correlate with with clinical or histologic parameters of disease activity. Colonic biopsies and peripheral blood samples will be collected from patients with UC before and after the onset of ozanimod. Researchers will compare intestinal and peripheral leukocytes before and after the drug's administration.

This description comes directly from the study's public registry record.

Talk to the study team

Jesus Rivera-Nieves, MD  ·  8585345495  ·  jriveran@ucsd.edu

Alyssa Blair  ·  858-822-4939

Always discuss trial participation with your own doctor first.

Locations (1)

University of California San DiegoSan Diego, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06311123